Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro ...

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly expands its diabetes and weight-loss drug, Mounjaro, to India, outpacing Novo Nordisk. The drug is priced ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...

Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, outpacing competitor Novo Nordisk. With ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Rep. Mariannette Miller-Meeks, R-Iowa, and colleagues introduced a version of the The bill would limit a PBM working with a ...